


PHARMACEUTICAL 2017



DYNAVAX TECHNOLOGIES CORP Rank 255 of 313





PHARMACEUTICAL 2017



DYNAVAX TECHNOLOGIES CORP Rank 255 of 313

The relative strengths and weaknesses of DYNAVAX TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DYNAVAX TECHNOLOGIES CORP compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 85% points. The greatest weakness of DYNAVAX TECHNOLOGIES CORP is the variable Research and Development, reducing the Economic Capital Ratio by 268% points.

The company's Economic Capital Ratio, given in the ranking table, is -553%, being 136% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	89,599
Cost of Goods Sold	0
Intangible Assets	1,971
Liabilities, Current	20,036
Liabilities, Non-Current	443
Other Assets	936
Other Compr. Net Income	-694
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,737
Property and Equipment	17,174
Research and Development	84,493
Revenues	11,043
Selling, General and Administrative Expense	37,257

Output Variable	Value in 1000 USD
Assets	109,680
Liabilities	20,479
Expenses	121,750
Stockholders Equity	89,201
Net Income	-112,444
Comprehensive Net Income	-112,791
Economic Capital Ratio	-553%